Using a stop removes the emotion from investing, which is always important, but it's especially important when investing in an emotional sector like biotech. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED One $8 Stock Could Help Put You on the Right Side of This Equation. [Click Here for Details] Editor's Note: Many of us grew up learning that "willpower" was all you needed to lose weight. In 2023, we know better. The true reason so many Americans are overweight may surprise you... And even better, there's an urgent investment opportunity that addresses this problem at its source. A new drug is about to hit the market... and data shows it's nearly twice as effective as Ozempic. Analysts project peak annual sales of $25 billion. Chief Income Strategist Marc Lichtenfeld recorded a video to get you up to speed on all the relevant details... Including the name and ticker symbol for the stock behind this "King Kong of weight loss drugs," as The Wall Street Journal calls it. (Yes, Marc gives away the name and ticker in the video itself - for free.) Click here to get the intel now. - Rachel Gearhart, Associate Publisher MARKET TRENDS The Secret to Investing in the Healthcare Sector Marc Lichtenfeld, Chief Income Strategist, The Oxford Club The healthcare sector is my favorite sector to invest in, both for the long and short term. Long term, demographics practically ensure that the sector will remain healthy (pun intended) for years to come. Every day, 10,000 baby boomers turn 65. A few decades from now, when the baby boomer population has dwindled, the next large population group (millennials) will be middle-aged. Short term, few sectors have the ability to produce such strong gains as healthcare, particularly biotech. But with these types of small cap biotech companies, it's easy to break one of investing's cardinal rules: Don't fall in love with a stock. My brother worked in the movie industry. Sometimes he was under a lot of pressure. When he felt stressed, he reminded himself, "You're either curing cancer or not curing cancer." In other words, people wouldn't die if his project wasn't successful. When you invest in small cap biotech stocks, you're often investing in companies that are trying to cure cancer, diabetes or a rare but fatal disease. The work that these companies do is important. If you buy shares of a stock like Target (NYSE: TGT), of course you want the company to prosper. And if Target's sales are strong, it will employ more people and help grow the economy. All good things. But let's face it, you probably don't get that excited about the same-store sales report each month. But when you invest in a small biotech, it's different. It's easy to become emotionally attached. For example, consider a company like Seagen (Nasdaq: SGEN), which is developing therapies for treating various cancers, including lymphoma, breast cancer and cervical cancer. You want the company to succeed, not only for your own monetary gain but because of the impact it could have on hundreds of thousands of lives. If things go wrong with some of these companies - like their drug getting rejected by the Food and Drug Administration (FDA) or their clinical trial data being weak - investors often make excuses and justify why they should stay in the stock, even if they have a large loss and the medical studies say the drug clearly doesn't work. And when things go right, they can go right in a hurry. Mersana Therapeutics (Nasdaq: MRSN) is a great example of how biotech stocks can experience big swings. The company's lead drug upifitamab rilsodotin (UpRi) relies on antibody-drug conjugates to treat ovarian cancer. SPONSORED WATCH NOW: Multimillionaire Trader Wows Thousands With "One Ticker Payouts" Demonstration Research found that smart investors could have made top gains of... 443% in 11 days 89% in 11 days 543% in nine days 88% in seven days. All by trading just one ticker every week! Sound preposterous? [SEE THE PROOF HERE] On April 26, Mersana's stock traded for $3.89. Due to promising data on ovarian cancer from ImmunoGen (Nasdaq: IMGN), the stock took off and eventually peaked at $9.62 on June 12. On June 15, Mersana announced that the FDA had paused enrollment in two studies on UpRi due to five deaths caused by excessive bleeding. The stock quickly came back to earth. By June 21, the stock closed at $2.98. Then, on July 27, Mersana announced more bad news regarding its studies on UpRi, and the stock fell from $3.91 to an intraday low of $0.80 the next day. As I write, the stock trades for around $1.30, roughly a third of where it was four months ago. Investors who were able to ride the stock to a high should have checked their emotions at the door and set a trailing stop. I recommend a 25% trailing stop on most stocks, meaning you adjust your stop higher as the stock goes higher. When Mersana hit its high at $9.62, an investor who set a 25% trailing stop would have gotten out at $7.21, which would've saved them about six points based on where it's trading today. It would have been easy to get caught up in the emotion of rooting for UpRi. The American Cancer Society estimates that nearly 20,000 women in the United States will be diagnosed with ovarian cancer in 2023. Of those diagnoses, about 13,000 will prove to be fatal. It makes sense to root for a product that can be beneficial to so many people. But setting a stop 25% below the high would have taken the emotion out of the trade and forced the sale of the stock at $7.21. Even if an investor was very hopeful that UpRi was going to save lives and be the next big thing in medicine, the stop would have taken them out of the position and saved them a lot of pain when Mersana tanked. Using a stop removes the emotion from investing, which is always important, but it's especially important when investing in an emotional sector like biotech. Good investing, Marc Leave a Comment RECOMMENDED LINKS One Potentially Explosive Stock That Alexander Green Just Discovered Has Seen Five-Year 2,000% Revenue Growth, Enjoys 70% Gross Margins and Sports a Debt-Free Balance Sheet, yet Still Trades Under $10. He's Calling It the "Next Great American Super Stock." (Click for Details.) Get Marc's Top 5 Dividend Stocks (FREE PICKS) MORE FROM WEALTHY RETIREMENT Fleetcor Technologies: Should You Invest? PEAK Stock: How Healthy Is This 5.9% Yield? How to Determine How Much to Contribute to Retirement Three Steps to Financial Independence Facebook Twitter Email Share Push Alert SPONSORED Shocking Free-for-All as Mass Looters Steal Cigarettes and Lottery Tickets Target saw $400 MILLION in mass theft losses last year. Rite Aid stock dropped 86% due to major shoplifting losses. Mass looting events are CRUSHING retail stocks. But this is just one symptom of a "woke disease" that is destroying our economy. Watch one stock legend take down the entire woke narrative right here. You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.